Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous CAR-T cells (Hebei Senlang Biotechnology)
- Development stage
- Unknown
- Lead developer
- Senlang Bio
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Administration
- Intravenous
01
Overview
Autologous chimeric antigen receptor T-cell (CAR-T) therapy developed by Hebei Senlang Biotechnology for the treatment of relapsed or refractory Non-Hodgkin lymphoma (NHL). This therapeutic approach involves genetically modifying a patient's own T cells to express chimeric antigen receptors (CARs) that specifically target antigens expressed on lymphoma cells, such as CD19, CD22, CD30, CD7, or CD79a. Once infused back into the patient, these engineered T cells recognize and eliminate malignant cells. The therapy is currently being evaluated in multicenter clinical trials to assess safety and efficacy across various NHL subtypes, including aggressive forms like Burkitt lymphoma and diffuse large B-cell lymphoma, as well as indolent forms like follicular lymphoma.
- Other names
- Auto CAR-Tauto CAR-T-Hebei Senlang Biotechnology Inc., Ltd.-Non-Hodgkin lymphoma
02
Targets
CD19 (B lymphocyte antigen CD19)CD30 (CD30 antigen)CD22 (Cluster of Differentiation 22)CD79A (CD79a molecule)CD7 (CD7 antigen)BCMA (B-cell maturation antigen)
Beyond the preview
Go deeper on autologous CAR-T cells (Hebei Senlang Biotechnology).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous CAR-T cells (Hebei Senlang Biotechnology).